build-out plan is premised on a number of factors, such as availability of sufficient financing on acceptable terms and achievement of satisfactory system performance in the relevant markets. To the extent such build-out plan would encompass market areas beyond those in which Nextel currently possesses sufficient holdings of spectrum, it would be dependent on the factors noted above and also on consummation of Nextel's currently pending or proposed transactions with other parties, including Motorola, Inc., OneComm Corporation, American Mobile Systems Incorporated and Dial Page, Inc.

3. As described in numerous Nextel documents and presentations, including the company's Annual Reports on Form 10–K for the fiscal years ended March 31, 1992, 1993, and 1994, as well as Nextel's interrogatory responses to the DOJ's Second Requests, Nextel's marketing strategy for its Digital Mobile network services is intended to be implemented in three stages. In the first stage, which Nextel currently is in now, Nextel is focusing its efforts on migrating its current dispatch-users to the digital mobile network. The second stage will concentrate on attracting new business users (e.g., current subscribers of traditional SMR or other two-way services), who may be especially attracted by the integrated package of services achievable through the new digital technology. The third stage will be geared towards a broader category of users, i.e., attracting potential customers who are interested in general mobile telephone service. Nextel expects to rely on its ability to provide an integrated package of digital wireless services in marketing itself to this segment as a viable and unique competitor providing services that are not only similar to those available from cellular operators and any other providers of mobile telephone services, but also paging and enhanced dispatch service providers.

4. Nextel expects that its mobile telephone services will be competitive with those offered by cellular providers and other providers of mobile telephone services in terms of quality of service, features offered, pricing structure and airtime utilization. In addition, Nextel believes that its ability to provide an integrated package of mobile communications services will appeal to a wide array of users of wireless communications services, including private network dispatch, paging and mobile telephone and mobile data transmission. Cellular providers currently do not directly provide such integrated services. Essentially, Nextel's business goal is to capture a significant share of the potential wireless customer base, not just the dispatch customers.

5. Nextel expects to charge rates that are competitive with those charged by other providers of wireless communications services. For example, Nextel's customers will pay only for the services used, with package pricing available for customers who subscribe to more than one service. If a customer uses digital dispatch, Nextel's charge is comparable to or reflects a slight premium over conventional analog dispatch rates, reflecting larger calling areas, higher quality transmission, and enhanced privacy. Similarly, a customer who uses Nextel's mobile telephone service will be charged rates comparable to those charged by cellular telephone providers and any other providers of mobile telephone services. Only where customers subscribe to services in addition to dispatch service will they be charged for such additional services capabilities, and accordingly, to the extent such customers utilize such an integrated digital wireless service package would they be likely to pay significantly more than they do today for dispatch.

6. Nextel's business and marketing plans are subject to periodic review and would, of course, be subject to adjustment as may from time to time be deemed advisable to respond to particular conditions affecting the economy generally, the evolving wireless services industry or the company specifically.

7. Motorola remains strongly committed to the success of its advanced digital technology, referred to as MIRS, and to its investment in Nextel.

Sworn to before me this 15 day of February, 1995.

Morgan E. O'Brien.

Clare Pugsley,

Notary Public District of Columbia.

[FR Doc. 95–8814 Filed 4–14–95; 8:45 am]

BILLING CODE 4410–01–M

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated February 17, 1995, and published in the **Federal Register** on March 1, 1995, 1994, (60 FR 11115), Organix Inc., 65 Cummings Park, Woburn, Massachusetts 01801, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Tetrahydrocannabinols (7370)	I
Morphine (9300)	II

No comments or objections have been received. Therefore, pursuant to Section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, § 1301.54(e), the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: April 7, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–9391 Filed 4–14–95; 8:45 am]

BILLING CODE 4410–09–M

Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with § 1311.42 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on February 9, 1995, Sigma Chemical Company, 3500 Dekalb Street, St. Louis, Missouri 63118, made application to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235)	I
Methcathinone (1237)	I
Fenethylline (1503)	I
Aminorex (1585)	I
Methaqualone (2565)	I
Alpha-Ethyltryptamine (7249)	I
Ibogaine (7260)	I
Lysergic acid diethylamide (7315)	I
Marihuana (7360)	I
Tetrahydrocannabinols (7370)	I
Mescaline (7381)	I
4-Bromo-2,5-dimethoxyamphetamine (7391).	I

Drug	Schedule
4-Bromo-2,5-dimethoxyphenethylamine (7392).	I
4-Methyl-2,5-dimethoxyamphetamine (7395).	I
2,5-Dimethoxyamphetamine (7396)	I
3,4-Methylenedioxyamphetamine (7400).	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402).	I
3,4-Methylenedioxymethamphetamine (7405).	I
4-Methoxyamphetamine (7411)	I
Bufotenine (7433)	I
Diethyltryptamine (7434)	I
Dimethyltryptamine (7435)	I
Psilocybin (7437)	I
Psilocyn (7438)	I
N-Ethyl-1-phenylcyclohexylamine (7455).	I
1-(1-Phenylcyclohexy)pyrrolidine (7458).	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470).	I
Etorphine (except HCl) (9056)	I
Difenoxin (9168)	I
Heroin (9200)	I
Morphine-N-oxide (9307)	I
Normorphine (9313)	I
1-Methyl-4-phenyl-4-propionoxypiperidine (9661).	I
3-Methylfentanyl (9813)	I
Alpha-methylfentanyl (9814)	I
Beta-hydroxyfentanyl (9830)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Pentobarbital (2270)	II
Secobarbital (2315)	II
Glutethimide (2550)	II
Phencyclidine (7471)	II
1-Piperidinocyclohexanecarbonitrile (8603).	II
Anileridine (9020)	II
Cocaine (9041)	II
Codeine (9050)	II
Diprenorphine (9058)	II
Benzoylecgonine (9180)	II
Ethylmorphine (9190)	II
Meperidine (9230)	II
Methadone (9250)	II
Dextropropoxyphene, bulk (non-dosage forms) (9273).	II
Morphine (9300)	II
Oxymorphone (9652)	II
Alfentanil (9737)	II
Sufentanil (9740)	II
Fentanyl (9801)	II

The firm plans to repackage the controlled substances in order to supply pure drugs for drug testing and analysis.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled substance may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.54 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than May 17, 1995.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1311.42(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745–46 (September 23, 1975), all applicants for registration to import a basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), (d), (e), and (f) are satisfied.

Dated: April 7, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–9392 Filed 4–14–95; 8:45 am]

BILLING CODE 4410–09–M

Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1311.42 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on February 23, 1995, Stepan Company, Natural Products Department, 100 W. Hunter Avenue, Maywood, New Jersey 07607, made application to the Drug Enforcement Administration to be registered as an importer of Coca Leaves (9040), a basic class of controlled substance in Schedule II.

The firm plans to import the Coca Leaves to manufacture Cocaine under its DEA manufacturers registration.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled substance may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.54 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than (30 days from publication).

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1311.42 (b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745–46 (September 23, 1975), all applicants for registration to import a basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42 (a), (b), (c), (d), (e), and (f) are satisfied.

Dated: April 7, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–9393 Filed 4–14–95; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF LABOR

Office of the Secretary

Women's Bureau; Commission on Family and Medical Leave; Public Hearing

AGENCY: Office of the Secretary, Labor.

ACTION: Notice of public hearing.

SUMMARY: Pursuant to Title III of the Family Medical Leave Act (FMLA) of 1993 (P.L. 103–3) this is to announce a hearing on the experience of FMLA for the Commission which is to take place on Monday, May 8, 1995. The purpose of the Commission is to, among other things, study the effects of existing and